Efficacy of ukrain in the treatment of pancreatic cancer.

Abstract

BACKGROUND:

This monocentric study evaluated the effect of ukrain in the treatment of pancreatic cancer.

MATERIAL AND METHODS:

Between January 1996 and December 1999 we treated 21 patients with 10 mg ukrain every second day x10. The control group received supportive treatment only.

RESULTS:

Ukrain treatment was well tolerated. Mean values on pain measure and Karnofsky index were significantly better in the ukrain group than in controls ( P<0.05). One-year survival was 76% in the ukrain group, compared to 9.5% in the control group. Median survival after treatment with ukrain was 574 days, compared to 197 days in the control group.

CONCLUSIONS:

Our data demonstrate that ukrain improves quality of life in patients suffering from advanced pancreatic cancer and significantly prolongs survival time in these patients.

• Authors: Volodimir Zemskov, Olga Prokopchuk, Yaroslav Susak, Sergiy Zemskov, Olexander Tkachenko, Yuriy Hodysh, Wassil Nowicky
• Journal: Langenbeck's archives of surgery (Langenbecks Arch Surg) Vol. 387 Issue 2 Pg. 84-9 (Jun 2002) ISSN: 1435-2443 [Print] Germany
• PMID: 12111260 (Publication Type: Journal Article)

Chemical References

• Alkaloids
• Antineoplastic Agents
• Berberine Alkaloids
• Phenanthridines
• ukrain

Topics

• Adult
• Aged
• Aged, 80 and over
• Alkaloids (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Berberine Alkaloids
• Female
• Humans
• Male
• Middle Aged
• Palliative Care
• Pancreatic Neoplasms (drug therapy, mortality)
• Phenanthridines
• Pilot Projects
• Prognosis
• Quality of Life